Vaxart, Inc. (VXRT) NASDAQ
0.70
+0.07000001(+11.11%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.70
+0.07000001(+11.11%)
Currency In USD
| Previous Close | 0.63 |
| Open | 0.63 |
| Day High | 0.7 |
| Day Low | 0.63 |
| 52-Week High | 0.84 |
| 52-Week Low | 0.26 |
| Volume | 200,077 |
| Average Volume | 549,533 |
| Market Cap | 168.99M |
| PE | 10 |
| EPS | 0.07 |
| Moving Average 50 Days | 0.66 |
| Moving Average 200 Days | 0.47 |
| Change | 0.07 |
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the ma
Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants
GlobeNewswire Inc.
Jan 15, 2026 1:00 PM GMT
Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of immunity to breastf
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
GlobeNewswire Inc.
Jan 08, 2026 9:01 PM GMT
SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, to